Medizinische Universität Graz - Research portal
Selected Publication:
Zuckermann, AO; Grimm, M; Czerny, M; Ofner, P; Ullrich, R; Ploner, M; Wolner, E; Laufer, G.
Improved long-term results with thymoglobuline induction therapy after cardiac transplantation: a comparison of two different rabbit-antithymocyte globulines.
Transplantation. 2000; 69(9):1890-1898
Doi: 10.1097/00007890-200005150-00026
Web of Science
PubMed
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Ofner-Kopeinig Petra
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND: The aim of this retrospective single center analysis was to compare possible long-term benefits of two different rabbit-antithymocyte globuline (ATG) induction therapies after cardiac transplantation. PATIENTS AND METHODS: A total of 484 primary cardiac transplanted patients received induction therapy with two different rabbit-ATGs (thymoglobuline: n=342, ATG-fresenius: n=142). All patients received immunosuppressive maintenance therapy with cyclosporine, azathioprine, and prednisolone. Cardiac rejection was assessed by serial endomyocardial biopsies. Surveillance of graft arteriosclerosis was performed by angiograms 1, 3, and 5 years after transplantation. RESULTS: Five-year survival was significantly better in the thymoglobuline group (76 vs. 60%). Thymoglobuline patients had a lower rate of death from rejection (2.3 vs. 10%; P<0.01) and graft arteriosclerosis (0.88 vs. 5.6%; P<0.01). After 5 years, freedom from rejection was 72% in the thymoglobuline group compared to 42% in the ATG-fresenius group (P<0.01). Graft arteriosclerosis appeared in 14% of thymoglobuline patients and in 28% of ATG-fresenius patients (P<0.01). Viral infections occurred more often in thymoglobuline patients (53 vs. 39%, P<0.05) although there was no difference in appearance of cytomegalovirus disease (17 vs. 13%). Freedom from posttransplant malignant disease was comparable between the two groups. CONCLUSION: These results suggest that there are differences between rabbit ATG products. The superior prevention of rejection with thymoglobuline may be the reason for the lower rate of graft arteriosclerosis.
- Find related publications in this database (using NLM MeSH Indexing)
- Adolescent -
- Adult -
- Aged -
- Animals -
- Antilymphocyte Serum - therapeutic use
- Child - therapeutic use
- Child, Preschool - therapeutic use
- Coronary Arteriosclerosis - etiology
- Female - etiology
- Graft Rejection - etiology
- Heart Transplantation - adverse effects
- Humans - adverse effects
- Immunosuppressive Agents - therapeutic use
- Male - therapeutic use
- Middle Aged - therapeutic use
- Multivariate Analysis - therapeutic use
- Neoplasms - etiology
- Rabbits - etiology
- T-Lymphocytes - immunology